Skin Cholesterol and New Coronary Artery Disease Risk Factors

This clinical trial will evaluate the relationship between skin cholesterol and a variety of new and established markers for coronary artery disease (CAD), including ankle/brachial blood pressure index (ABI) and vascular compliance, in high-risk patients. The study is taking place at Providence Hospital, in Vancouver, British Columbia, which is affiliated with the University of British Columbia (UBC). The trial is conducted in collaboration with AtCor Medical Pty. Ltd, an Australia-based company that specializes in cardiovascular diagnostic products, and UBC.

One hundred patients at high risk for cardiovascular disease not currently taking cholesterol-lowering medication will be examined using PREVU* Point of Care (POC) Skin Sterol Test, a non-invasive cardiovascular disease risk assessment test, as well as the lab-processed format of the technology, PREVU* LT Skin Sterol Test. Another marker included in the trial is AtCor’s SphygmoCor Px Aortic BP Profile System, a tool that derives the calibrated blood pressure waveform from radial artery blood pressure, which is also measured non-invasively. Markers of inflammation, markers produced by fat cells, and specialized lipid tests, among others, are also be included in the study.